Zacks Investment Research Upgrades CV Sciences (CVSI) to “Hold”

CV Sciences (OTCMKTS:CVSI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.

According to Zacks, “CV Sciences Inc. is a life science company. Its operating segment consists of specialty pharmaceuticals and consumer products. Specialty pharma business segment is focused on developing and commercializing therapeutics utilizing synthetic Cannabidiol across several therapeutic areas. Consumer product business segment is focused on manufacturing, marketing and selling plant-based CBD products. It operates primarily in San Diego, California and Las Vegas, Nevada. CV Sciences Inc. is based in Las Vegas, United States. “

Separately, Northland Securities started coverage on shares of CV Sciences in a report on Thursday, January 24th. They issued an “outperform” rating and a $8.00 target price for the company.

CVSI stock opened at $5.60 on Monday. CV Sciences has a fifty-two week low of $0.51 and a fifty-two week high of $9.20. The firm has a market capitalization of $541.35 million, a P/E ratio of 62.22 and a beta of -0.72.

CV Sciences (OTCMKTS:CVSI) last posted its earnings results on Tuesday, March 12th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.01. CV Sciences had a net margin of 20.73% and a return on equity of 41.83%. The firm had revenue of $14.22 million during the quarter, compared to analyst estimates of $14.91 million. As a group, research analysts predict that CV Sciences will post 0.11 EPS for the current year.

CV Sciences Company Profile

CV Sciences, Inc operates as a life science company. It operates through two segments, Specialty Pharmaceuticals and Consumer Products. The company focuses on developing and commercializing prescription drugs utilizing synthetic cannabidiol (CBD) as the active pharmaceutical ingredient. Its initial drug candidate is CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction.

See Also: Cost of Equity

Get a free copy of the Zacks research report on CV Sciences (CVSI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CV Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CV Sciences and related companies with MarketBeat.com's FREE daily email newsletter.